Vaxart (NASDAQ:VXRT – Get Free Report) and NKGen Biotech (NYSE:NKGN – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.
Institutional & Insider Ownership
18.0% of Vaxart shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 2.6% of Vaxart shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings for Vaxart and NKGen Biotech, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vaxart | 0 | 0 | 2 | 0 | 3.00 |
| NKGen Biotech | 0 | 0 | 0 | 0 | 0.00 |
Profitability
This table compares Vaxart and NKGen Biotech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vaxart | -431.61% | -110.46% | -62.78% |
| NKGen Biotech | N/A | N/A | -479.36% |
Risk & Volatility
Vaxart has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
Valuation & Earnings
This table compares Vaxart and NKGen Biotech”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vaxart | $28.70 million | 3.01 | -$82.46 million | ($0.34) | -1.12 |
| NKGen Biotech | $80,000.00 | 87.65 | -$82.94 million | ($2.45) | -0.06 |
Vaxart has higher revenue and earnings than NKGen Biotech. Vaxart is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.
Summary
Vaxart beats NKGen Biotech on 8 of the 14 factors compared between the two stocks.
About Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
About NKGen Biotech
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.
